- Gilead Sciences has begun enrolling patients into two Phase IIstudies of its nucleotide analog drug GS 840 (adefovir dipivoxil). The oral tablet has potential in the treatment of chronic hepatitis B virus infection, says the company. In one trial, one of three doses of GS 840 will be administered daily to 60 patients with normal liver enzyme levels over a period of 12 weeks. The second trial will enroll 60 patients with elevated liver enzyme levels, a sign of HBV.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze